Further, a folate-conjugated TLR7 agonist showed in vivo activity in assorted tumor models and reversed expression of a high M2-like to M1-like macrophage ratio and increased the infiltration of cytotoxic CD8 T cells20. Here, CD8A is linked to neoplasm.